小脑
激酶
泛素连接酶
极光抑制剂
极光A激酶
极光激酶
癌症研究
细胞周期进展
化学
细胞生物学
泛素
生物
细胞
细胞周期
生物化学
基因
作者
Jelena Božilović,Lorenz Eing,Benedict‐Tilman Berger,Bikash Adhikari,Janik Weckesser,Nicola Berner,Stephanie Wilhelm,Bernhard Küster,Elmar Wolf,Stefan Knapp
标识
DOI:10.1016/j.crchbi.2022.100032
摘要
The family of AURORA kinases is essential for cell cycle progression and dysregulation of AURORA-A in cancer led to a large number of clinical and pre-clinical inhibitors. However, ATP competitive AURORA-A inhibitors usually do not target non-catalytic functions that have also been identified as mechanisms promoting tumorigenesis. To target non-catalytic as well as catalytic functions, we developed a series of PROTACs (PROteolysis TArgeting Chimeras) based on the selective AURORA-A kinase inhibitor MK-5108 (VX-689) and the CEREBLON E3-ligase ligand thalidomide. The most potent PROTAC, JB301, had good physicochemical properties and cell penetration resulting in degradation of AURORA-A in leukemic cells at single digit nM concentration.
科研通智能强力驱动
Strongly Powered by AbleSci AI